The Evolving Treatment Landscape of Merkel Cell Carcinoma
- 5 July 2023
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (9) , 1231-1258
Abstract
Opinion statement Merkel cell carcinoma (MCC) has a high risk of recurrence and requires unique treatment relative to other skin cancers. The patient population is generally older, with comorbidities. Multidisciplinary and personalized care is therefore paramount, based on patient preferences regarding risks and benefits. Positron emission tomography and computed tomography (PET-CT) is the most sensitive staging modality and reveals clinically occult disease in ~ 16% of patients. Discovery of occult disease spread markedly alters management. Newly diagnosed, localized disease is often managed with sentinel lymph node biopsy (SLNB), local excision, primary wound closure, and post-operative radiation therapy (PORT). In contrast, metastatic disease is usually treated systemically with an immune checkpoint inhibitor (ICI). However, one or more of these approaches may not be indicated. Criteria for such exceptions and alternative approaches will be discussed. Because MCC recurs in 40% of patients and early detection/treatment of advanced disease is advantageous, close surveillance is recommended. Given that over 90% of initial recurrences arise within 3 years, surveillance frequency can be rapidly decreased after this high-risk period. Patient-specific assessment of risk is important because recurrence risk varies widely (15 to > 80%: Merkelcell.org/recur) depending on baseline patient characteristics and time since treatment. Blood-based surveillance tests are now available (Merkel cell polyomavirus (MCPyV) antibodies and circulating tumor DNA (ctDNA)) with excellent sensitivity that can spare patients from contrast dye, radioactivity, and travel to a cancer imaging facility. If recurrent disease is locoregional, management with surgery and/or RT is typically indicated. ICIs are now the first line for systemic/advanced MCC, with objective response rates (ORRs) exceeding 50%. Cytotoxic chemotherapy is sometimes used for debulking disease or in patients who cannot tolerate ICI. ICI-refractory disease is the major problem faced by this field. Fortunately, numerous promising therapies are on the horizon to address this clinical need.Keywords
This publication has 93 references indexed in Scilit:
- Radiotherapy is associated with significant improvement in local and regional control in Merkel cell carcinomaRadiation Oncology, 2012
- The Role of Radiotherapy Alone in Patients With Merkel Cell Carcinoma: Reporting the Australian Experience of 43 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Radiation monotherapy as regional treatment for lymph node‐positive Merkel cell carcinomaCancer, 2010
- Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU featuresJournal of the American Academy of Dermatology, 2008
- Palliative Radiotherapy Trials for Bone Metastases: A Systematic ReviewJournal of Clinical Oncology, 2007
- Merkel Cell Carcinoma: Does Tumor Size or Depth of Invasion Correlate With Recurrence, Metastasis, or Patient Survival?The Laryngoscope, 2006
- Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markersHistopathology, 2005
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.Genes & Development, 1994
- A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone painRadiotherapy and Oncology, 1992